论文部分内容阅读
作者研究了抗人白细胞介素-2受体(IL2-R)的单克隆抗体(McAb)33B3.1(大鼠IgG2a型McAb)预防初次尸肾移植后两周排斥反应的临床效果。作者将27例初次尸肾移植受者分两组:A组9例每日静脉注射33B3.1 5mg;B组18例每日静注10mg。两组均自移植当日起连续14天,同时口服强的松及硫唑嘌呤,14天后加服环孢素。实验中发生排斥反应时,加用抗胸腺细胞球蛋白(ATG)治疗。实验设两个对照组:C组为历史对照,30例病人均为1982年以前肾移植受者,用强的松及硫唑嘌呤抗排斥反应;D组55人,除用ATG代替McAb外,
The authors investigated the clinical effect of anti-human interleukin-2 receptor (IL2-R) monoclonal antibody (McAb) 33B3.1 (rat IgG2a McAb) in preventing two-week rejection after primary cadaveric kidney transplantation. The authors divided 27 first-time cadaver kidney transplant recipients into two groups: Group A 9 patients daily intravenous injection 33B3.1 5mg; Group B 18 patients daily intravenous injection 10mg. Both groups were given 14 consecutive days from the day of transplantation, while prednisone and azathioprine were orally administered, and cyclosporine was given after 14 days. Exclusion reaction occurred in the experiment, plus anti-thymocyte globulin (ATG) treatment. In the experiment, two control groups were set up: Group C was a historical control. All 30 patients were renal transplant recipients before 1982 with anti-rejection activity of prednisone and azathioprine. 55 patients in group D, except ATG instead of McAb,